Best of Targeted Therapies of Lung Cancer (TTLC) 2025-Best of TTLC Recording

Video Transcription

Video Summary

The webinar, hosted by Dr. Rebecca Heist and Dr. Antoinette Wozniak, focused on the latest advancements in lung cancer treatments. Dr. Suresh Gagil discussed first-line treatment options for metastatic EGFR-mutant lung cancer, emphasizing the significant advancements in treatment over the past three years. He highlighted the FLORA trial, which demonstrated the survival benefits of osimertinib, especially for patients with classical EGFR mutations. Dr. Gagil also addressed newer therapeutic options for atypical and exon 20 mutations, highlighting the ongoing trials and the evolving landscape of lung cancer treatment.<br /><br />Dr. Natasha Lael provided insights into perioperative therapies for early-stage lung cancer, emphasizing the role of precision medicine, especially for EGFR and ALK-driven tumors. She outlined the strategies for using chemotherapy and immunotherapy either before, after, or in a sandwich approach around surgery, stressing the importance of genotyping and multidisciplinary care.<br /><br />Dr. Jonathan Reese discussed new immune oncology targets, focusing on bispecific and bispecific T cell engagers. He highlighted the potential of these therapies in attacking multiple immune pathways and their emerging role in cancer treatment, with Tarlatumab already FDA approved for extensive-stage small cell lung cancer.<br /><br />The webinar concluded with a Q&A session, discussing the nuanced choices between combination therapies for EGFR-mutant lung cancer and emphasizing the importance of shared decision-making based on individual patient profiles and the latest data.

Keywords

lung cancer

EGFR mutations

osimertinib

FLORA trial

precision medicine

perioperative therapies

immune oncology

T cell engagers

Tarlatumab

shared decision-making